Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (8): 493-497.doi: 10.3760/cma.j.cn371439-20230525-00094

• Reviews • Previous Articles     Next Articles

Research progress of Nrf2 in ovarian cancer

An Rong1, Liu Meihua1, Wang Peichen1, Wang Xiaohui2()   

  1. 1 First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
    2 Department of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou 730000, China
  • Received:2023-05-25 Revised:2023-07-02 Online:2023-08-08 Published:2023-10-24
  • Contact: Wang Xiaohui E-mail:xiaohuiwang2015@163.com
  • Supported by:
    Natural Science Foundation of Gansu Province of China(20JR5RA361)

Abstract:

Nuclear factor-erythroid 2-related factor 2 (Nrf2) is an important transcription factor that regulates redox, lipid metabolism and protein dynamic balance, and plays an important role in protecting the body from oxidative stress damage. Recently, more and more studies have shown that Nrf2 is activated in ovarian cancer by various mechanisms to induce increased antioxidant enzymes, change sex hormone metabolism and induce downstream targets. Further studying the mechanism of Nrf2 in promoting the development of ovarian cancer, exploring its role in drug resistance and seeking new therapeutic targets can provide new ideas for the treatment of drug-resistant ovarian cancer.

Key words: Ovarian neoplasms, NF-E2-related factor 2, Antineoplastic combined chemotherapy protocols, Drug resistance, neoplasm